坚持药物治疗以预防冠心病的二次预防:基于注册表的前性研究
Aradhai Bana1, Krishna Kumar Sharma2, Soneil Guptha3
1Norwich Medical School, University of East Anglia, Norwich, NR47TJ, UK.
Indian heart journal
|February 28, 2025
概括
在印度,急性冠状动脉综合征 (ACS) 后的药物坚持率低于最佳,在六个月内,关键的二次预防药物显著下降. 需要策略来改善患者对这些救命疗法的坚持.
科学领域:
- 心脏病学 心脏病学
- 药物治疗 药物治疗
- 公共卫生 公共卫生
背景情况:
- 有限的数据存在二次预防药物坚持后急性冠状动脉综合征 (ACS) 在印度.
- 了解坚持模式对于改善ACS患者的长期结果至关重要.
研究的目的:
- 评估在印度ACS住院后对推的二次预防药物的坚持.
- 为了确定药物使用的趋势和在出院后六个月的药物坚持.
主要方法:
- 一项基于注册表的研究,涉及连续的ACS患者.
- 数据收集包括人口统计,基线特征,住院干预和出院药物 (抗血小板药物,他类药物,β-阻断剂,ACEI/ARB,CCB).
- 六个月的随访使用验证的工具评估了药物坚持.
主要成果:
- 在出院后,阿司匹林 (97.3%),双抗血小板药 (99.7%) 和他类药物 (99.7%) 的初始处方率很高.
- 六个月后药物使用的显著下降:阿司匹林 (83.9%),双抗血小板药物 (70.2%),他类药物 (70.0%),β阻塞剂 (50.4%),ACEI/ARB (22.4%).
- 总体而言,只有42.7%的患者 (≥80%) 具有良好的坚持性;政府赞助的保险与更好的坚持性相关.
结论:
- 在ACS和皮肤冠状动脉干预 (PCI) 后,对二次预防药物治疗的坚持在六个月后是不理想的.
- 观察到使用各种基本药物的显著下降 (16-42%).
- 迫切需要制定和实施加强遵守的战略.
相关概念视频
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
596
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
596
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464